This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (173)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

Is This a Cause for Concern?

George L. Bakris, MD; Matthew R. Weir, MD

Arch Intern Med. 2000;160:685-693.

Background  Reducing the actions of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors (ACEIs) slows nephropathy progression in patients with or without diabetes. Post hoc analyses of many ACEI-based clinical trials demonstrate the greatest slowing of renal disease progression in patients with the greatest degree of renal insufficiency at study initiation. However, many physicians fail to use ACEIs or angiotensin receptor blockers in patients with renal insufficiency for fear that either serum creatinine or potassium levels will rise.

Objective  To determine if limited initial reduction in either glomerular filtration rate (GFR) or elevation in serum creatinine levels, associated with ACEI or angiotensin receptor blocker use, results in long-term protection against decline in renal function in patients with renal insufficiency.

Methods  We reviewed 12 randomized clinical trials that evaluated renal disease progression among patients with preexisting renal insufficiency. Six of these studies were multicenter, double-blinded, and placebo controlled, with the remainder being smaller randomized studies with a minimum 2-year follow-up on renal function. These investigations evaluated patients with and without diabetes or systolic heart failure. Average duration of follow-up for all studies was 3 years. Trials were examined in the context of changes in either serum creatinine levels or GFR in the group randomized to an ACEI (N=1102). Sixty-four percent of these individuals (705/1102) had renal function data at both less than 6 months and at the end of the study.

Results  Most trials demonstrated that patients with preexisting renal insufficiency manifested an acute fall in GFR, a rise in serum creatinine, or both. Those randomized to an ACEI with a serum creatinine level of 124 µmol/L or greater (1.4 mg/dL) demonstrated a 55% to 75% risk reduction in renal disease progression compared with those with normal renal function randomized to an ACEI. An inverse correlation was observed between the amount of renal function loss at baseline and the subsequent rate of annual decline in renal function following randomization to an antihypertensive regimen that contained an ACEI.

Conclusions  A strong association exists between acute increases in serum creatinine of up to 30% that stabilize within the first 2 months of ACEI therapy and long-term preservation of renal function. This relationship holds for persons with creatinine values of greater than 124 µmol/L (>1.4 mg/dL). Thus, withdrawal of an ACEI in such patients should occur only when the rise in creatinine exceeds 30% above baseline within the first 2 months of ACEI initiation, or hyperkalemia develops, ie, serum potassium level of 5.6 mmol/L or greater.

From the Rush University Hypertension/Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian–St Luke's Medical Center, Chicago, Ill (Dr Bakris), and Division of Nephrology, Department of Medicine, University of Maryland Medical Center, Baltimore (Dr Weir).

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(5):718-719.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis
Onuigbo and Onuigbo
QJM 2008;101:519-527.
ABSTRACT | FULL TEXT  

The role of percutaneous revascularization for renal artery stenosis
Dubel and Murphy
Vasc Med 2008;13:141-156.
ABSTRACT  

Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease
van Domburg et al.
J. Am. Soc. Nephrol. 2008;19:158-163.
ABSTRACT | FULL TEXT  

Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials
Phillips et al.
Arch Intern Med 2007;167:1930-1936.
ABSTRACT | FULL TEXT  

Effect of Nesiritide Infusion Duration on Renal Function in Acutely Decompensated Heart Failure Patients
Chow et al.
The Annals of Pharmacotherapy 2007;41:556-561.
ABSTRACT | FULL TEXT  

Best practice in primary care pathology: review 6
Smellie et al.
J. Clin. Pathol. 2007;60:225-234.
ABSTRACT | FULL TEXT  

Monitoring renal function in hypertension.
Martin and Coleman
BMJ 2006;333:896-899.
FULL TEXT  

Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications: [Revue sommaire sur les implications anesthesiques de l'oedeme de Quincke et des inhibiteurs de l'enzyme de conversion de l'angiotensine].
Sarkar et al.
Canadian J. Anesthesia 2006;53:994-1003.
ABSTRACT | FULL TEXT  

Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose et al.
J. Am. Soc. Nephrol. 2006;17:2886-2891.
ABSTRACT | FULL TEXT  

Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.
Parikh et al.
Arch Intern Med 2006;166:1884-1891.
ABSTRACT | FULL TEXT  

Diabetic Nephropathy: Where We Have Been and Where We Are Going
Ossman
Diabetes Spectr. 2006;19:153-156.
ABSTRACT | FULL TEXT  

Therapeutic conversion from fosinopril to benazepril at a Veterans Affairs medical center.
Gates et al.
Am J Health Syst Pharm 2006;63:1066-1068.
FULL TEXT  

A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica et al.
Nephrol Dial Transplant 2006;21:1389-1394.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou et al.
NEJM 2006;354:131-140.
ABSTRACT | FULL TEXT  

Atherosclerotic renovascular disease in chronic heart failure: should we intervene?
de Silva et al.
Eur Heart J 2005;26:1596-1605.
ABSTRACT | FULL TEXT  

Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death
Main
Heart 2005;91:548-552.
FULL TEXT  

Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure
Sackner-Bernstein et al.
Circulation 2005;111:1487-1491.
ABSTRACT | FULL TEXT  

Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses
Chiurchiu et al.
J. Am. Soc. Nephrol. 2005;16:S58-S63.
ABSTRACT | FULL TEXT  

Optimal care of lupus nephritis patients
Jadoul
Lupus 2005;14:72-76.
ABSTRACT  

Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
Gross et al.
Diabetes Care 2005;28:164-176.
ABSTRACT | FULL TEXT  

Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results
Remuzzi et al.
J. Am. Soc. Nephrol. 2004;15:3117-3125.
ABSTRACT | FULL TEXT  

The Clinical Challenge of Cardiorenal Syndrome
Shlipak and Massie
Circulation 2004;110:1514-1517.
FULL TEXT  

Guidelines for Hypertension: Are Quality-Assurance Measures on Target?
Singer et al.
Hypertension 2004;43:198-202.
ABSTRACT | FULL TEXT  

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises
Palmer
Nephrol Dial Transplant 2003;18:1973-1975.
FULL TEXT  

The Endocrine Society Meeting: Topics in Insulin Sensitivity and Hypertension
Bloomgarden
Diabetes Care 2003;26:2679-2688.
FULL TEXT  

Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment
Flack et al.
J. Am. Soc. Nephrol. 2003;14:S92-98.
ABSTRACT | FULL TEXT  

Nephrology: 4. Strategies for the care of adults with chronic kidney disease
Stigant et al.
CMAJ 2003;168:1553-1560.
FULL TEXT  

Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency
Shlipak
ANN INTERN MED 2003;138:917-924.
ABSTRACT | FULL TEXT  

Treating Hypertension in Diabetic Nephropathy
Tomlinson et al.
Diabetes Care 2003;26:1802-1805.
ABSTRACT | FULL TEXT  

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
Chobanian et al.
JAMA 2003;289:2560-2571.
ABSTRACT | FULL TEXT  

Looking for people at high cardiovascular risk? Look at serum-creatinine
Mann et al.
Eur Heart J 2003;24:381-383.
FULL TEXT  

Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial
Hillege et al.
Eur Heart J 2003;24:412-420.
ABSTRACT | FULL TEXT  

Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial
Wright et al.
JAMA 2002;288:2421-2431.
ABSTRACT | FULL TEXT  

Renal Dysfunction Complicating the Treatment of Hypertension
Palmer
NEJM 2002;347:1256-1261.
FULL TEXT  

ACE Inhibitors to Prevent End-Stage Renal Disease: When to Start and Why Possibly Never to Stop: A Post Hoc Analysis of the REIN Trial Results
Ruggenenti et al.
J. Am. Soc. Nephrol. 2001;12:2832-2837.
ABSTRACT | FULL TEXT  

Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy: A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association
Schoolwerth et al.
Circulation 2001;104:1985-1991.
FULL TEXT  

Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial
Agodoa et al.
JAMA 2001;285:2719-2728.
ABSTRACT | FULL TEXT